ABT Group’s Vitamin C formulation Mirakle found paving the way for faster recovery from Covid-19

LN Revathy Coimbatore | Updated on May 08, 2020 Published on May 08, 2020

While no targeted antiviral medications or vaccines are yet available to fight the Novel Coronavirus (Covid-19) disease, ABT Group’s Vitamin C formulation – Mirakle – has been found to pave the way for faster recovery, a company release said.

Manickam Mahalingam, Group Chairman and the brain behind Mirakle Wellness Clinic in Pollachi, said the drink has been cleared for supply to Covid-19 patients at Rajiv Gandhi General Hospital and Omandurar Hospital in Chennai, apart from being administered to patients at the General Hospital in Cuddalore.

Manickam has always maintained that the focus of the treatment should be on the Mitochondria of the body to enable immunity to handle viral infections.

Mirakle enhances the functioning of the Mitochondria by making vitamin C, Lysine and Proline available in a proper ratio within a nano-particle wrapped with Phospholipids, he said, and pointed out that the supply clearance to administer the formulation to Covid-19 patients and the outcome in managing the casualties of this pandemic were not only medical wins but also a personal win.

“Studies show that Vitamin C has always been an immunity booster. We have used the standard protocol and definition of this to heal our patients. We look forward to reaching out to more of those affected through Mirakle and strongly believe that this is the road to recovery. The focus of the treatment is to support the metabolism of the body to support itself and to fight against foreign viruses,” he said

Sharing a comparative study, he said, a batch of 50 patients were given 500 mg of regular vitamin C a day, while another 50 (treatment batch) were given Mirakle (a formulation which contained 4 gm of palatable liposomal vitamin C ) a day.

At the end of the third, fifth and seventh days, the patients were reviewed. There was symptomatic improvement in the treatment batch.

Treatment with high dose of liposomal vitamin C is really useful when given with other drugs, he said.

Published on May 08, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.